Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma
Excerpt:
Confirming the specificity of the rescue, SRCT341I cells also showed increased resistance to saracatinib and bosutinib, but not ponatinib, which is designed to overcome this gatekeeper mutation.